Skip to content

GROOVE BOTANICALS, INC.: 10-Q filed 2024-11-14

What GROOVE BOTANICALS, INC. reported in its quarterly report filed 2024-11-14 (fiscal Q2 2025): 23 published measures, 72 facts as tagged in accession 0001171520-24-000360.

This filing

Form
10-Q (quarterly report)
Filed
2024-11-14
Fiscal period
fiscal Q2 2025
Accession
0001171520-24-000360 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GROOVE BOTANICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-3011,125USD
At 2024-03-312,142USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-30947,289USD
At 2024-03-31762,699USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-30-936,164USD
At 2024-06-30-851,713USD
At 2024-03-31-760,557USD
At 2023-09-30-625,505USD
At 2023-06-30-540,843USD
At 2023-03-31-438,298USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-09-306,133USD
At 2024-03-311,688USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-29,833USD92
2024-04-01 to 2024-09-30-66,372USD183
2023-07-01 to 2023-09-30-30,045USD92
2023-04-01 to 2023-09-30-156,272USD183

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-04-01 to 2024-09-30-63,468USD183
2023-04-01 to 2023-09-30-50,822USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-04-01 to 2024-09-3067,913USD183
2023-04-01 to 2023-09-3049,102USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-35,022,884USD
At 2024-03-31-34,847,277USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2024-09-3059,643,062shares92
2024-04-01 to 2024-09-3059,643,062shares183
2023-07-01 to 2023-09-3058,643,062shares92
2023-04-01 to 2023-09-3058,561,905shares183

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-07-01 to 2024-09-3059,643,062shares92
2024-04-01 to 2024-09-3059,643,062shares183
2023-07-01 to 2023-09-3058,643,062shares92
2023-04-01 to 2023-09-3058,561,905shares183

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-07-01 to 2024-09-300USD/shares92
2024-04-01 to 2024-09-300USD/shares183
2023-07-01 to 2023-09-300USD/shares92
2023-04-01 to 2023-09-300USD/shares183

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-07-01 to 2024-09-300USD/shares92
2024-04-01 to 2024-09-300USD/shares183
2023-07-01 to 2023-09-300USD/shares92
2023-04-01 to 2023-09-300USD/shares183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-29,833USD92
2024-04-01 to 2024-09-30-66,372USD183
2023-07-01 to 2023-09-30-27,795USD92
2023-04-01 to 2023-09-30-151,772USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-3011,125USD
At 2024-03-312,142USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-30947,289USD
At 2024-03-31762,699USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-3029,833USD92
2024-04-01 to 2024-09-3066,372USD183
2023-07-01 to 2023-09-3027,795USD92
2023-04-01 to 2023-09-30151,772USD183

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2024-07-01 to 2024-09-3018,332USD92
2024-04-01 to 2024-09-3034,931USD183
2023-07-01 to 2023-09-3021,852USD92
2023-04-01 to 2023-09-3038,816USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-09-3059,643,062shares
At 2024-03-3159,643,062shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-09-306,133USD
At 2024-03-311,688USD
At 2023-09-302,846USD
At 2023-03-314,566USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-09-3034,026,869USD
At 2024-03-3134,026,869USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-29,833USD92
2024-04-01 to 2024-06-30-36,539USD91
2023-07-01 to 2023-09-30-30,045USD92
2023-04-01 to 2023-06-30-126,227USD91

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-84,452USD92
2024-04-01 to 2024-09-30-175,607USD183
2023-07-01 to 2023-09-30-84,663USD92
2023-04-01 to 2023-09-30-265,507USD183

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-2,250USD92
2023-04-01 to 2023-09-30-4,500USD183

Inspect the source

Entity
GROOVE BOTANICALS, INC. / CIK 0000918573
Captured
2026-09-20T05:07:38.101Z
SEC response SHA-256
44d2b85f5a8268e7e4b9e515e1ab70f7e4cebdb379a9107709d6545a3e823130

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000918573.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))